Decreased Intracellular Superoxide Levels Activate Sindbis Virus-induced Apoptosis*

Kuo-I LinDagger §, Piera PasinelliDagger , Robert H. BrownDagger , J. Marie Hardwick§, and Rajiv R. RatanDagger parallel **

From the Dagger  Department of Neurology, Harvard Medical School, and the parallel  Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115,  Massachusetts General Hospital, Boston, Massachusetts 02129, and the § Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Infection of many cultured cell types with Sindbis virus (SV), an alphavirus, triggers apoptosis through a commonly utilized caspase activation pathway. However, the upstream signals by which SV activates downstream apoptotic effectors, including caspases, remain unclear. Here we report that in AT-3 prostate carcinoma cells, SV infection decreases superoxide (Obardot 2) levels within minutes of infection as monitored by an aconitase activity assay. This SV-induced decrease in Obardot 2 levels appears to activate or modulate cell death, as a recombinant SV expressing the Obardot 2 scavenging enzyme, copper/zinc superoxide dismutase (SOD), potentiates SV-induced apoptosis. A recombinant SV expressing a mutant form of SOD, which has reduced SOD activity, has no effect. The potentiation of SV-induced apoptosis by wild type SOD is because of its ability to scavenge intracellular Obardot 2 rather than its ability to promote the generation of hydrogen peroxide. Pyruvate, a peroxide scavenger, does not affect the ability of wild type SOD to potentiate cell death; and increasing the intracellular catalase activity via a recombinant SV vector has no effect on SV-induced apoptosis. Moreover, increasing intracellular Obardot 2 by treatment of 3T3 cells with paraquat protects them from SV-induced death. Altogether, our results suggest that SV may activate apoptosis by reducing intracellular superoxide levels and define a novel redox signaling pathway by which viruses can trigger cell death.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Apoptosis is a genetically controlled process, with distinct morphological and biochemical features, by which cells commit suicide during development and in disease states (1, 2). Sindbis virus (SV),1 an alphavirus, belongs to the growing list of viruses (3-10) that can trigger apoptosis in infected host cells in vitro or in vivo. The elimination of virus-infected cells via apoptosis is believed to be a mechanism used by the host to limit the spread of progeny virus to neighboring cells and thus to decrease the host viral burden (11). However, if the primary targets in vivo are nonreplenishing cells like neurons, virus-induced apoptosis can also have devastating consequences for the host. For example, age-dependent encephalitis and mortality induced by SV is correlated with the ability of SV to induce apoptosis in neurons in the central nervous system of mice (12, 13).

Mechanistic studies of SV-induced apoptosis indicate that SV engages an apoptotic pathway used by many death stimuli (14). CrmA, a caspase-inhibitory protein encoded by cowpox virus (15), inhibits SV-induced apoptosis in cultured cells and reduces SV-induced mortality in mice (14). SV-induced death can also be blocked by the pluripotent anti-apoptotic protein, Bcl-2 (8, 16). These data suggest that SV triggers a common death execution pathway, but the state changes induced by SV which set this common pathway in motion remain unclear.

Maintenance of the cellular redox balance is believed to play an important role in regulating survival (17), and multiple lines of evidence indicate that disruption of the redox equilibrium in favor of oxidants, a condition defined as "oxidative stress," may activate apoptosis (18-20). In cultured cells, the addition of oxidants or inhibition of antioxidant defenses leads to apoptosis (18-20). Similarly, overexpression of antioxidant enzymes or treatment of cells with antioxidants has been shown to prevent apoptotic death (21-24). Apoptosis induced by a disruption in redox homeostasis appears to be a mechanism of neuronal loss in a broad range of sporadic and inherited neuropathological disorders, including Parkinson's disease (25), Alzheimer's disease (26), amyotrophic lateral sclerosis (27), and Huntington's disease (28). Moreover, genetic studies indicate that inherited mutations in antioxidant defenses may also induce neuropathology (29, 30). For example, a subset of patients with a familial form of amyotrophic lateral sclerosis have been found to carry mutations in the gene encoding the antioxidant enzyme, copper/zinc superoxide dismutase (Cu,Zn-SOD) (29, 31, 32). Mutations in the Cu,Zn-SOD gene appear to diminish the threshold for activation of apoptosis in neurons, and antioxidants can restore the threshold for activation of cell death to levels seen in cells carrying wild type Cu,Zn-SOD (33). Taken together, these observations suggest that oxidative stress is a mediator of apoptotic death, although cell death induced by certain stimuli can be triggered independent of oxidative stress (34, 35).

To examine whether apoptosis induced by SV is activated by oxidative stress, we previously evaluated the effects of antioxidants on SV-induced apoptosis in cultured cells (36). Our results showed that a host of antioxidants, including metal chelators, inhibitors of lipid peroxidation, or scavengers of peroxide failed to inhibit SV-induced apoptosis, suggesting that oxidative stress is not a mediator of SV-induced death (36). However, we did not monitor directly individual reactive oxygen species (ROS), such as superoxide (Obardot 2) or peroxide (H2O2), so we could not definitively exclude a role for these ROS in regulating SV-induced death. In this study, we examine the role of Obardot 2 and H2O2 in SV-induced apoptosis.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Viability Studies-- AT-3 rat prostate carcinoma cells and 3T3 fibroblasts were cultured as described previously (36, 37). For viability studies, 103 AT-3 cells/well or 104 3T3 fibroblasts/well were seeded in 96-well plates. 1 day after plating, recombinant SVs were added at a multiplicity of infection (m.o.i.) of 10 plaque-forming units/cell. Cell viability was determined by measuring the cell-associated lactate dehydrogenase activity as described previously (37). For the experiments involving pyruvate and paraquat (1,1'-dimethyl-4,4'-bipyridinum dichloride) (Sigma), AT-3 cells or 3T3 fibroblasts were pretreated with pyruvate or paraquat for 1 h and then infected with recombinant SVs. Viability assays were performed 24 h later as described above.

Generation of Recombinant Virus-- A cDNA fragment containing Cu,Zn-SOD (SOD wt) or Cu,Zn-SOD with a glycine to serine mutation at codon 41 (SOD M) was cut from the PstI/EcoRI sites of PVL1392 and was then blunt end ligated into the BstEII site of an SV vector (dsTE12Q) in forward and reverse orientations. A polymerase chain reaction-amplified DNA fragment containing catalase of Hemophilus influenza from pWB5 plasmid (a gift from Dr. William Bishai) (38) was also blunt end ligated into the BstEII site of a recombinant SV vector in forward and reverse orientations. These recombinant SV vectors were linearized with XhoI and then transcribed in vitro with SP6 RNA polymerase (Life Technologies, Inc.). The resultant RNA transcripts were transfected into baby hamster kidney cells by the LipofectAMINE method as described previously (37). Recombinant SVs were harvested from the supernatant of the culture media of the transfected baby hamster kidney cells. Viral titers were determined by standard plaque assays as described previously.

Immunoblotting-- 106 AT-3 cells were infected with recombinant SV-SODs (wt, M or reverse (R)) at an m.o.i. of 10. 16 h postinfection, cells were lysed as described previously (37). 20 µg of protein from cytoplasmic extracts was boiled in Laemmli buffer and electrophoresed under reducing conditions on 15% polyacrylamide gels. Proteins were then transferred to a polyvinylidene difluoride membrane (Bio-Rad). Nonspecific binding was inhibited by incubation in Tris-buffered saline and Tween (50 mM Tris-HCl, pH 8.0, 0.9% NaCl, 0.1% Tween 20) containing nonfat dried milk for 2 h. Human SOD antibody was diluted in 1% milk, Tris-buffered saline and Tween at 1:5,000. After exposure of membranes to horseradish peroxidase-conjugated secondary antibody for 1.5 h, immunoreactive proteins were detected according to the enhanced chemiluminescent protocol (Amersham Pharmacia Biotech).

Aconitase Assay-- 106 AT-3 cells or 3T3 fibroblasts were either infected with SV (AR339) at an m.o.i. of 25 or treated with paraquat. At various intervals after paraquat treatment or SV infection, cells were lightly trypsinized, pelleted, and resuspended in 100 µl of reaction mixture containing 50 mM Tris-HCl, pH 7.4, 30 mM sodium citrate, 0.6 mM MnCl2, 0.2 mM NADP+, and 1 unit/ml isocitrate dehydrogenase (39-41). Cells were then homogenized by Tekmar Tissumizer for 10 s in the reaction mixture, and aconitase activity was then determined by the absorbance increase at 340 nm at 25 °C for 30 min in a Molecular Devices SpectraMax 250 thermostatted microplate UV-visible spectrophotometer. The results were expressed as (aconitase activity from each time point/aconitase activity from mock infected or mock treated cells) × 100%.

SOD Activity Measurement-- SOD activity was determined by an indirect inhibition assay developed by Oberley and Spitz (42). Briefly, 4 × 105 AT-3 cells were either mock infected or infected with recombinant SV-SODs (wt, M, or R) at an m.o.i. of 10 for 16 h and were then trypsinized. Cell pellets were resuspended in 100 µl of potassium phosphate buffer (50 mM, pH 7.8) and then were homogenized by Tekmar Tissumizer for 1 min. 10 µg of cell homogenates was used for determining SOD activity in 200 µl of reagent containing 50 mM potassium phosphate buffer, pH 7.8, 5.6 × 10-5 M nitro blue tetrazolium, 0.1 mM xanthine, and 0.002 unit of xanthine oxidase. The SOD activity of cell lysates was measured spectrophotometrically by monitoring the suppression of superoxide-induced formation of formazan from nitro blue tetrazolium at 560 nm for 5 min.

Catalase Activity Measurement-- Catalase activity was measured as described by Aebi (43). 4 × 105 AT-3 cells were mock infected or infected with recombinant SV-catalase (forward and reverse) for 20 h. Cell extracts were then prepared as described above. 10 µg of cell extracts was added to 100 µl of 10 mM H2O2 in 50 mM potassium phosphate buffer, pH 7.8, and the rate of loss of absorbance of H2O2 at 240 nm was monitored for 30 s in a Beckman DU-50 spectrophotometer.

Sindbis Virus Production-- 105 AT-3 cells or 3T3 fibroblasts were grown in 12-well plates and were infected with recombinant SV-SOD viruses at an m.o.i. of 10. 2 h after infection, cells were washed three times with phosphate-buffered saline, and then the infectious media were harvested at 4, 8, and 24 h postinfection. Virus titers were determined by standard plaque assay on baby hamster kidney cells. For paraquat experiments, 3T3 fibroblasts were treated with 250 µM paraquat 1 h prior to virus infection, and viabilities were assessed as described above at the indicated intervals.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Infection with SV Reduces Intracellular Superoxide Levels in AT-3 Rat Prostate Carcinoma Cells-- Aconitase activity is a sensitive and specific assay for measuring intracellular Obardot 2 levels in mammalian cells (44). To test whether Obardot 2 levels change prior to SV-induced apoptosis, we assayed aconitase activity after SV (AR339) infection in AT-3 rat prostate carcinoma cells. Previous studies have established that SV (AR399) triggers cell death with morphological and biochemical features of apoptosis 18-24 h after infection in this cell line (8, 36). SV (AR339) increased aconitase activity within minutes of binding to and/or infecting AT-3 cells, suggesting that SV decreases Obardot 2 prior to the onset of apoptosis (Fig. 1). To verify that aconitase activity is a valid measure of Obardot 2 levels in AT-3 cells, we exposed these cells to paraquat, a redox cycling agent capable of generating Obardot 2 intracellularly. As expected, we found that paraquat reduces aconitase activity beginning 5 min after drug exposure (Fig. 1).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   SV infection increases aconitase activity in AT-3 cells. AT-3 cells were infected with SV (AR339) () at an m.o.i. of 25, and aconitase activity was determined at the indicated time points as described under "Materials and Methods." In parallel, AT-3 cells treated with paraquat (diamond ) were also harvested for aconitase activity assays. The percentage of aconitase activity was determined as (aconitase activity from each time point/aconitase activity from mock infected/treated cells) × 100%. Results represent the mean value from three to five independent experiments ± S.E.

Recombinant SV Expressing Wild Type SOD (SV-SOD1 wt) Potentiates SV-induced Apoptosis-- To determine whether decreases in Obardot 2 levels regulate SV-induced apoptosis, we generated a recombinant SV that carries the wild type human Cu,Zn-SOD gene (SV-SOD wt). As controls, we inserted a mutated form of the human Cu,Zn-SOD gene (SV-SOD M) and the wild type human Cu,Zn-SOD gene in the reverse orientation (SV-SOD R), into the SV vector. SOD1 is a cytosolic enzyme that catalyzes the conversion of Obardot 2 into H2O2. The mutated form of SOD1 used in this study has a glycine to serine mutation at codon 41. This mutation, which is predicted to disrupt the integrity of the beta  sheet initiated at codon 41 and the adjoining active site loop containing the copper ion, was identified previously in a pedigree of familial amyotrophic lateral sclerosis patients and has been shown to cause a significant reduction in SOD1 activity in cultured lymphoblasts of affected patients compared with SOD1 activity in lymphoblasts from controls (32).

Infection of AT-3 cells with SV-SOD wt significantly enhances cell death compared with infection with recombinant SV-SOD M or recombinant SV-SOD R (Fig. 2A). The potentiating effect of wild type SOD1 on SV-induced apoptosis is also observed in 3T3 fibroblasts where 47, 70, or 65% of cells survive after infection with SV-SOD wt, SV-SOD M, or SV-SOD R, respectively (not shown).


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 2.   SV-SOD1 wt, but not SV-SOD1 M or SV-SOD1 R, potentiates SV-induced apoptosis. Panel A, cell viability of AT-3 cells infected with recombinant SV-SOD wt (dotted bar), SV-SOD M (gray bar), and SV-SOD R (black bar) at 24 h postinfection. A small and reproducible level of cell death (<3%) was observed in mock infected cultures as monitored by phase-contrast microscopy, lactate dehydrogenase, or 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Results are expressed as the mean ± S.E. from three independent experiments. Panel B, increased SOD activity in recombinant SV-SOD wt-infected cells. AT-3 cells infected with or without recombinant SV-SODs for 16 h were harvested for SOD activity assay. Results represent the mean ± S.E. from six independent experiments. White bar, control; other bars as in panel A. Panel C, immunoblot verified that similar levels of heterologous SOD were expressed in recombinant SV-SOD wt- and SV-SOD M-infected cells at 16 h postinfection. N.S. refers to a nonspecific band.

SOD enzymatic activity was determined in lysates of mock, SV-SOD wt-, SV-SOD M-, or SV-SOD R-infected AT-3 cells. As expected, cells infected with SV-SOD wt significantly increased SOD enzymatic activity (1.7-fold) compared with mock infected cells. By contrast, SOD activity in AT-3 cells infected with SV-SOD M or SV-SOD R is not significantly different from mock infected cells (Fig. 2B). The differences in SOD activity between SV-SOD wt- or SV-SOD M-infected cells could not be attributed to different levels of heterologous SOD protein expression as monitored by immunoblot analysis (Fig. 2C).

To evaluate whether wild type SOD potentiates cell death by facilitating SV replication, viral titers were assessed in AT-3 cells infected with each recombinant virus. SV-SOD wt, SV-SOD M, and SV-SOD R replicate with equal efficiency at early time points after infection and prior to the appearance of apoptotic morphology (Fig. 3). At 24 h postinfection, the virus production was slightly lower in cells infected with SV-SOD wt compared with virus production of cells infected with SV-SOD M and SV-SOD R. The difference in viral titers detected at later time points likely relates to the decreased viability of cells infected with SV-SOD wt (Fig. 3). Taken together, our results suggest that decreased intracellular Obardot 2 levels enhance SV-induced apoptosis without affecting virus replication.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 3.   Recombinant SV-SOD wt (black-square), SV-SOD M (diamond ), and SV-SOD R (open circle ) replicate at similar rates in AT-3 cells. Supernatants from AT-3 cells infected with recombinant SVs were collected at 4, 8, and 24 h postinfection, and plaque assay was performed in duplicate in baby hamster kidney cells. Results are expressed as the mean ± S.E. from three independent experiments. Error bars are hidden by the symbols.

Inhibition of H2O2 Generation by Pyruvate Does Not Prevent the Potentiating Effect of Wild Type SOD on SV-induced Apoptosis-- Enforced expression of wild type SOD has been shown to result in increased steady-state levels of hydrogen peroxide (H2O2) (45). Hydrogen peroxide can induce cytotoxicity by reacting with transition metals such as iron to form highly reactive hydroxyl radicals. To examine whether enhanced generation of H2O2 by wt SOD contributes to the death-promoting effect of recombinant SV-SOD wt, we treated 3T3 fibroblasts with pyruvate, a nonenzymatic scavenger of peroxide (46), 1 h prior to infection with recombinant SV-SOD wt, SV-SOD M, or SV-SOD R. Although 2 mM pyruvate completely inhibits cytotoxicity induced by 200 µM hydrogen peroxide in 3T3 (Fig. 4B) or AT-3 cells (not shown), pyruvate (2 mM or 10 mM) has no effect on the potentiation of SV-induced death by wild type SOD1 (Fig. 4A). These results suggest that potentiation of cell death by SV-SOD is not mediated through peroxide. However, we cannot exclude the possibility that SV induces metabolic barriers that prevent intracellular pyruvate from reaching a concentration required for peroxide scavenging.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Pyruvate, a peroxide scavenger, does not reverse the potentiating effect of wild type SOD on SV-induced apoptosis in 3T3 fibroblasts. Panel A, 3T3 fibroblasts were pretreated with 2 mM or 10 mM pyruvate for 1 h and then infected with recombinant SV-SODs. Cell viability was determined by lactate dehydrogenase assay at 24 h postinfection, and the results are presented as the mean ± S.E. from three independent experiments. A small and reproducible amount of cell death (<3%) was observed in mock infected cultures. Dotted bars, SV-SOD wt; gray bars, SV-SOD M; black bars, SV-SOD R. Panel B, 3T3 fibroblasts were pretreated with 2 mM pyruvate for 1 h and then treated with 200 µM H2O2. Cell viability was determined after 5 h of H2O2 treatment. Results are expressed as the mean ± S.E. from three experiments. Error bars are hidden by the symbols.

To examine more definitively the role of H2O2 in SV-induced apoptosis, we generated a recombinant SV carrying a catalase gene from H. influenza (SV-Cat.). Catalase is an antioxidant enzyme that catalyzes H2O2 into H2O and O2. As a control, we inserted catalase in the reverse orientation into the SV vector. Catalase activity measurements confirmed that infection of AT-3 cells with SV-Cat. resulted in increased levels of catalase activity compared with mock or SV-Cat. R-infected cells (Fig. 5A). To determine the effects of enhanced catalase activity on SV-induced apoptosis, we measured the viability of cells infected with various recombinant viruses at several time points after infection. As shown in Fig. 5B, we found that SV-Cat. and SV-Cat. R triggered cell death with similar kinetics in AT-3 cells.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 5.   Enforced expression of catalase using the recombinant SV vector does not affect SV-induced death. Panel A, AT-3 cells infected with recombinant SV-Cat. (dotted bar) have elevated levels of catalase activity compared with mock infected (white bar) or SV-Cat. R-infected cells (black bar). AT-3 cells were either mock infected or infected with recombinant SV-Cat. for 20 h and were then harvested for catalase assay. Results represent the mean ± S.E. from four experiments. Panel B, cell viability of AT-3 cells infected with recombinant SV-Cat. () and SV-Cat. R (diamond ) at 24 and 48 h postinfection. Results were expressed as the mean ± S.E. from three independent experiments.

Taken together, these results are consistent with the notion that the potentiating effects of wt SOD on SV-induced death relate to decreased Obardot 2 levels and not increased or decreased peroxide levels. Furthermore and consistent with our previous observations (36, 47), these data demonstrate that H2O2 is not a regulator of SV-induced apoptosis.

Increasing Intracellular Superoxide by Paraquat Protects from SV-induced Apoptosis-- If decreases in superoxide trigger SV-induced death, then increases in intracellular Obardot 2 should abrogate SV cytotoxicity. To address this hypothesis, we treated 3T3 fibroblasts with 250 µM paraquat 1 h prior to infection with SV-SOD wt, SV-SOD M, and SV-SOD R. At 24 h postinfection, 250 µM paraquat significantly inhibits cell death induced by SV-SOD wt, SV-SOD M, and SV-SOD R (Fig. 6A).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   Paraquat, a Obardot 2 generator, inhibits SV-induced apoptosis in 3T3 fibroblasts. Panel A, 3T3 cells were pretreated with 100 µM or 250 µM paraquat and were then infected with recombinant SV-SODs 1 h later at an m.o.i. of 10. Cell viability was determined at 24 h postinfection, and the results are expressed as the mean ± S.E. from three experiments. Dotted bars, control; gray bars, 100 µM paraquat; black bars, 250 µM paraquat. Panel B, paraquat does not significantly influence recombinant SV-SOD wt replication. 3T3 fibroblasts were treated with 250 µM paraquat and then infected with recombinant SV-SOD wt 1 h later at an m.o.i. of 10. Recombinant SV-SOD wt produced in 3T3 fibroblasts cultured supernatants was collected at the indicated times postinfection, and plaque assay was performed as described under "Materials and Methods." Results represent the mean ± S.E. from three independent experiments. , SV-SOD wt; diamond , SV-SOD wt + paraquat.

To determine whether paraquat impairs SV replication, virus production from infected 3T3 fibroblasts with or without the treatment of paraquat was measured. Concentrations of paraquat which impair apoptosis do not interfere with virus replication at 4, 8, and 24 h postinfection (Fig. 6B).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Stable overexpression of individual antioxidant enzymes in cell lines has been shown to result in increased or decreased levels of other antioxidant enzymes in these lines (48, 49). For example, overexpression of SOD1 in NIH/3T3 cells has been shown to alter endogenous glutathione peroxidase, manganase superoxide dismutase, and glutathione transferase activities (48). Under these circumstances, the primary biological effects of modulating the levels of a single antioxidant enzyme may be difficult to evaluate. The recombinant SV expression system overcomes this problem by allowing the expression of heterologous proteins after infection, avoiding the need to generate stable cell lines and limiting the amount of time in which secondary changes can occur. Moreover, because recombinant SV can also induce apoptosis, the role of the expressed heterologous proteins in regulating apoptosis can be evaluated (15, 16, 37). Herein, we used the recombinant SV system to overexpress SOD1 or catalase in AT-3 cells and to demonstrate a role for Obardot 2 but not peroxide in regulating SV-induced death.

Several observations suggest that SV infection leads to reduced intracellular Obardot 2 levels, leading to activation of cell death. First, aconitase activity, an in situ measure whose levels are inversely proportional to Obardot 2 levels (50), increases almost immediately after SV infection. Second, expression of the Obardot 2 scavenger, SOD, in a recombinant SV vector, accelerates SV-induced apoptosis, whereas a mutated form of SOD, with impaired enzymatic activity, does not (Fig. 2A). Third, the Obardot 2 generator, paraquat, inhibits SV-induced apoptosis (Fig. 6A). These results suggest that intracellular Obardot 2 may inhibit components of the death machinery required for SV-induced apoptosis. Of note, intracellular Obardot 2 has also been shown to be an endogenous inhibitor of Fas-induced apoptosis (51), suggesting that Fas- and SV-induced death may engage similar cell death pathways. Indeed, previous evidence supports the notion that Fas- and SV-induced apoptosis might activate a similar death pathway because both Fas- and SV-induced apoptosis are sensitive to CrmA, a highly specific inhibitor of caspases 1, 4, 5, or 8 (14).

Several lines of evidence indicate that Cu,Zn-SOD has a protective role in regulating apoptosis. For example, microinjection of Cu,Zn-SOD delays nerve growth factor deprivation-induced apoptosis in sympathetic neurons (23). Also, overexpression of Cu,Zn-SOD inhibits apoptosis induced by serum or growth factor withdrawal or calcium ionophore treatment in nigral neural cells (52). Moreover, transgenic Drosophila that carry a mutated Cu,Zn-SOD gene appeared to have a shortened lifespan (53), whereas selective overexpression of the wild type Cu,Zn-SOD gene in motor neurons of Drosophila with defective Cu,Zn-SOD recover 60% of their lifespan (54). In mammals, mice lacking Cu,Zn-SOD are more sensitive to axonal injury (55). These converging lines of inquiry suggest that Cu,Zn-SOD can promote survival in some circumstances. In contrast, transgenic mice overexpressing Cu,Zn-SOD appeared to have significantly fewer thymocytes and are more susceptible to lipopolysaccharide-mediated loss of thymocytes (56). Moreover, neurons derived from transgenic mice overexpressing Cu,Zn-SOD also showed higher susceptibility to kainic acid-induced apoptosis (57). Therefore, constitutive expression of a Obardot 2 scavenging enzyme may also sensitize cells to certain kinds of stimuli; these observations are consistent with our observations that overexpression of Cu,Zn-SOD exacerbates SV-induced apoptosis.

In contrast to established schemes whereby ROS are increased prior to the activation of apoptosis (58), we find that intracellular ROS, specifically Obardot 2 levels, are decreased soon after SV infection (Fig. 1). The mechanism by which SV triggers the decrease of intracellular Obardot 2 is still unclear. However, this finding combined with our previous observation that SV infection leads to increased intracellular glutathione levels (36) suggests that SV may activate the apoptotic pathway by perturbing the redox equilibrium toward a reduced state rather than an oxidized state. Of note, a decreased production of ROS has also been shown to be an early event in dexamethasone-induced apoptosis in thymocytes (59), suggesting a more general role for "reductive stress" in activating cell death.

What are the putative targets modified by decreased levels of intracellular Obardot 2 which regulate SV-induced death? Our results suggest that decreasing intracellular Obardot 2 does not facilitate SV replication because recombinant SV -SOD1 wt replicates as well as the SV-SOD1 M and SV-SOD1 R (Fig. 3). Additionally, paraquat protects from SV-induced apoptosis and does not alter SV replication (Fig. 6B). Therefore, it seems likely that Obardot 2 may play a role in changing the activity of as yet unidentified cellular targets involved in regulating SV-induced apoptosis. Obardot 2 itself is capable of inactivating certain kinases, such as mammalian creatine phosphokinase (60) and the NADH dehydrogenase complex of the mitochondrial electron transport chain (61); however, the roles of these proteins in apoptosis are still unknown. Another potential target of Obardot 2 are the caspases-cysteine-dependent proteases whose activity has been shown to be altered by redox-active agents (62). It is unlikely that the target modulated by superoxide levels which negatively regulates SV-induced cell death is aconitase or its iron-deficient analog IRP-1, as previous studies from our laboratory showed that the iron chelators do not inhibit SV-induced death in AT3 cells (36). If decreased IRP-1 activity or increased aconitase activity were the mechanism by which the apoptotic signal is mediated, then iron chelators, which enhance IRP-1 activity and decrease aconitase activity (63), should attenuate SV-induced death.

In addition to Obardot 2, nitric oxide has also been shown to inhibit SV-induced apoptosis in cultured cells and diminish SV-mediated mortality in mice (64). Treatment of fetal mice with a nitric oxide synthase inhibitor potentiates SV-induced encephalitis and mortality; in addition, treatment of N18 neuroblastoma cells with nitric acid donors enhances cell survival after SV infection. These results combined with our observations suggest that Obardot 2 and nitric oxide are the free radical species that negatively regulate SV-induced apoptosis.

Previously, we have demonstrated that SV-induced apoptosis may not result from the generation of ROS, as a panel of antioxidants failed to protect from SV-induced apoptosis (36). Here, in an extension of our previous study, we demonstrate that inhibition of intracellular Obardot 2 levels is required for SV-induced apoptosis. These results not only provide insight into the mechanism by which SV transduces its death signal but also broaden the concept of oxidative stress-induced apoptosis; that is, reductive stress may also trigger cells to undergo apoptosis.

    ACKNOWLEDGEMENTS

We thank Drs. Ron Morton and Carl W. White for providing the aconitase activity assay protocol and Dr. Khalequz Zaman for providing SOD activity assay and catalase activity assay protocols. We thank Dr. William. R. Bishai for the pWB5 plasmid and Dr. Bruce Demple for helpful suggestions.

    FOOTNOTES

* This work was supported by Grants NINDS R29, NS34943, and KO8 NS01951 from the National Institutes of Health (to R. R. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Dept. of Neurology, Harvard Medical School and the Beth Israel Deaconess Medical Center, 77 Avenue Louis Pasteur, Rm. 857, Boston, MA 02115. Tel.: 617-667-0802; Fax: 617-667-0800; E-mail: rratan{at}caregroup.harvard.edu.

    ABBREVIATIONS

The abbreviations used are: SV, Sindbis virus; Cu, Zn-SOD, copper/zinc superoxide dismutase; ROS, reactive oxygen species; Obardot 2, superoxide; m.o.i., multiplicity of infection; SOD wt, wild type Cu,Zn-SOD; SOD M, Cu,Zn-SOD with a glycine to serine mutation at codon 41; SOD R, reverse Cu,Zn-SOD; SV-Cat., SV carrying a catalase gene from H. influenza..

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Jacobson, M. D., Weil, M., and Raff, M. C. (1997) Cell 88, 347-354[Medline] [Order article via Infotrieve]
  2. Thompson, C. B. (1995) Science 267, 1456-1462[Medline] [Order article via Infotrieve]
  3. Kawanishi, M. (1993) J. Virol. 67, 7654-7658[Abstract]
  4. Morey, A. L., Ferguson, D. J. P., and Fleming, K. A. (1993) J. Pathol. 169, 213-220[Medline] [Order article via Infotrieve]
  5. Meyaard, L., Otto, S. A., Jonker, R. R., Miinster, M. J., Keet, R. P. M., and Miedema, F. (1992) Science 257, 217-219[Medline] [Order article via Infotrieve]
  6. Esolen, L. M., Park, S. W., Hardwick, J. M., and Griffin, D. E. (1995) J. Virol. 69, 3955-3958[Abstract]
  7. Hinshaw, V. S., Olsen, C. W., Dybdahl-Sissoko, N., and Evans, D. (1994) J. Virol. 68, 3667-3673[Abstract]
  8. Levine, B., Huang, Q., Isaacs, J. T., Reed, J. C., Griffin, D. E., and Hardwick, J. M. (1993) Nature 361, 739-742[CrossRef][Medline] [Order article via Infotrieve]
  9. Tolskaya, E. A., Romanova, L. I., Kolesnikova, M. S., Ivasnnikova, T. A., Smirnova, E. A., Raikhlin, N. T., and Agol, V. I. (1995) J. Virol. 69, 1181-1189[Abstract]
  10. Eleouet, J. F., Chilmonczyk, S., Besnardeau, L., and Laude, H. (1998) J. Virol. 72, 4918-4924[Abstract/Free Full Text]
  11. Shen, Y., and Shenk, T. E. (1995) Curr. Opin. Genet. Dev. 5, 105-111[Medline] [Order article via Infotrieve]
  12. Griffin, D. E., Levine, B., Tyor, W. R., Tucker, P. C., and Hardwick, J. M. (1994) Arch. Virol. 9, 31-39
  13. Lewis, J., Wesselingh, S. L., Griffin, D. E., and Hardwick, J. M. (1996) J. Virol. 70, 1828-1835[Abstract]
  14. Nava, V. E., Rosen, A., Veliuona, M. A., Clem, R. J., Levine, B., and Hardwick, J. M. (1998) J. Virol. 72, 452-459[Abstract/Free Full Text]
  15. Ray, C. A., Black, R. A., Kronheim, S. R., Greenstreet, T. A., Sleath, P. R., Salvesen, G. S., and Pickup, D. J. (1992) Cell 69, 597-604[Medline] [Order article via Infotrieve]
  16. Levine, B., Goldman, J. E., Jiang, H. H., Griffin, D. E., and Hardwick, J. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4810-4815[Abstract/Free Full Text]
  17. Buttke, T. M., and Sandstrom, P. A. (1994) Immunol. Today 15, 7-10[CrossRef][Medline] [Order article via Infotrieve]
  18. Lennon, S. V., Martin, S. J., and Cotter, T. G. (1991) Cell Prolif. 24, 203-214[Medline] [Order article via Infotrieve]
  19. Zhong, L.-T., Sarafian, R., Kane, D. J., Charles, A. C., Mah, S. P., Edwards, R. H., and Bredesen, D. E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4533-4537[Abstract]
  20. Larrick, J. W., and Wright, S. C. (1990) FASEB J. 4, 3215-3223[Abstract]
  21. Ferrari, G., Yan, C. Y. I., and Greene, L. A. (1995) J. Neurosci. 15, 2857-2866[Abstract]
  22. Mayer, M., and Noble, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7596-7600
  23. Greenlund, L. J. S., Deckwerth, T. L., and Johnson, E. M., Jr. (1995) Neuron 14, 303-315[Medline] [Order article via Infotrieve]
  24. Ratan, R. R., Murphy, T. M., and Baraban, J. M. (1994) J. Neurosci. 14, 4385-4392[Abstract]
  25. Fariello, R. G. (1988) Funct. Neurol. 3, 407-412[Medline] [Order article via Infotrieve]
  26. Cotman, C. W., and Anderson, A. J. (1995) Mol. Neurobiol. 10, 19-45[Medline] [Order article via Infotrieve]
  27. Mu, X., He, J., Anderson, D. W., Trojanowski, J. Q., and Springer, J. E. (1996) Ann. Neurol. 40, 379-386[Medline] [Order article via Infotrieve]
  28. Portera-Calliau, C., Hedreen, J. C., Price, D. L., and Koliatosis, V. E. (1995) J. Neurosci. 13, 3669-3680[Abstract]
  29. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., Rahmani, Z., Krizus, A., McKenna-Yasek, D., Cayabyab, A., Gaston, S. M., Berger, R., Tanzi, R. E., Haperin, J. J., Herzfeldt, B., Van den Bergh, R., Hung, W.-Y., Bird, T., Deng, G., Mulder, D. W., Smyth, C., Laing, N. G., Soriano, E., Pericak-Vance, M. A., Haines, J., Rouleau, G. A., Gueslla, J. F., Horvitz, H. R., and Brown, R. H., Jr. (1993) Nature 362, 59-62[CrossRef][Medline] [Order article via Infotrieve]
  30. Brown, R. H., Jr. (1995) Cell 80, 687-692[Medline] [Order article via Infotrieve]
  31. Siddique, T., Figlewicz, D. A., Pericak-Vance, M. A., Haines, J. L., Rouleau, G., Jeffers, A. J., Sapp, P., Hung, W.-Y., Bebout, J., McKenna-Yasek, D., Deng, G., Horvitz, H. R., Gusella, J. S. J. F., Brown, R. H., Jr., and Roses, A. D. (1991) N. Engl. J. Med. 324, 1381-1384[Abstract]
  32. Tsuda, T., Munthasser, S., Fraser, P. E., Percy, M. E., Rainero, I., Vaula, G., Pinessi, L., Bergamini, L., Vignocchi, G., Crapper McLachlan, D. R., Tatton, W. G., and St. George-Hyslop, P. (1994) Neuron 13, 727-736[Medline] [Order article via Infotrieve]
  33. Rabizadeh, S., Gralla, E. B., Borchelt, D. R., Gwinn, R., Valentine, J. S., Sisodia, S., Wong, P., Lee, M., Hahn, H., and Bredesen, D. E. (1995) Proc. Natl. Acad. Sci U. S. A. 92, 3024-3028[Abstract]
  34. Shimizu, S., Eguchi, Y., Kosaka, H., Kamiile, W., Matsuda, H., and Tsujimoto, Y. (1995) Nature 374, 811-813[CrossRef][Medline] [Order article via Infotrieve]
  35. Jacobson, M. D., and Raff, M. C. (1995) Nature 374, 814-816[CrossRef][Medline] [Order article via Infotrieve]
  36. Lin, K.-I., Lee, S.-H., Narayanan, R., Baraban, J. M., Hardwick, J. M., and Ratan, R. R. (1995) J. Cell Biol. 131, 1149-1161[Abstract]
  37. Lin, K.-I., DiDonato, J. A., Hoffmann, A., Hardwick, J. M., and Ratan, R. R. (1998) J. Cell Biol. 141, 1479-1487[Abstract/Free Full Text]
  38. Bishai, W. R., Smith, H. O., and Barcak, G. J. (1994) J. Bacteriol. 176, 2914-2921[Abstract]
  39. Gardner, P. R., and Fridovich, I. (1991) J. Biol. Chem. 266, 19328-19333[Abstract/Free Full Text]
  40. Gardner, P. R., Nguyen, D.-D. H., and White, C. W. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12248-12252[Abstract/Free Full Text]
  41. Gardner, P. R., Raineri, I., Epstein, L. B., and White, C. W. (1995) J. Biol. Chem. 270, 13399-13405[Abstract/Free Full Text]
  42. Oberley, L. W., and Spitz, D. R. (1984) Methods Enzymol. 105, 457-464[Medline] [Order article via Infotrieve]
  43. Aebi, H. (1984) Methods Enzymol. 105, 121-126[Medline] [Order article via Infotrieve]
  44. Fridovich, I. (1997) J. Biol. Chem. 272, 18515-18517[Free Full Text]
  45. Freeman, B. A., and Crapo, J. D. (1982) Lab. Invest. 47, 412-426[Medline] [Order article via Infotrieve]
  46. Desagher, S., Glowinski, J., and Premont, J. (1997) J. Neurosci. 17, 9060-9067[Abstract/Free Full Text]
  47. Esch, F., Lin, K.-I., Hills, A., Zaman, K., Baraban, J. M., Chatterjee, S., Rubin, L., Ash, D. E., and Ratan, R. R. (1998) J. Neurosci. 18, 4083-4095[Abstract/Free Full Text]
  48. Kelner, M. J., and Bagnell, R. (1990) J. Biol. Chem. 265, 10872-10875[Abstract/Free Full Text]
  49. Amstad, P., Peskin, A., Shah, G., Mirault, M.-E., Moret, R., Zbinden, I., and Cerutti, P. (1991) Biochemistry 30, 9305-9313[Medline] [Order article via Infotrieve]
  50. Patel, M., Day, B. J., Crapo, J. D., Fridovich, I., and McNamaram, J. O. (1996) Neuron 16, 345-355[Medline] [Order article via Infotrieve]
  51. Clément, M.-V., and Stamenkovic, I. (1996) EMBO J. 15, 216-225[Abstract]
  52. Rabizadeh, S., Gralla, E. B., Borchelt, D. R., Gwinn, R., Valentine, J. S., Sisodia, S., Wong, P., Lee, M., Hahn, H., and Bredesen, D. E. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3024-3028[Abstract]
  53. Philllips, J. D., Campbell, S. D., Michaud, D., Charbonneau, M., and Hilliker, A. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2761-2765[Abstract]
  54. Parkes, T. L., Elia, A. J., Dickinson, D., Hilliker, A. J., Phillips, J. P., and Boulianne, G. L. (1998) Nat. Genet. 19, 171-174[CrossRef][Medline] [Order article via Infotrieve]
  55. Reaume, A. G., Elliott, J. L., Hoffman, E. K., Kowall, N. W., Ferrante, R. J., Siwek, D. F., Wilcox, H. M., Flood, D. G., Beal, M. F., Brown, R. H., Jr., Scott, R. W., and Snider, W. D. (1996) Nat. Genet. 13, 43-47[Medline] [Order article via Infotrieve]
  56. Peled-Kamar, M., Lotem, J., Okon, E., Sachs, L., and Groner, Y. (1995) EMBO J. 14, 4985-4993[Abstract]
  57. Bar-Peled, O., Korkotian, E., Segal, M., and Groner, Y. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8530-8535[Abstract/Free Full Text]
  58. Tan, S., Sagara, Y., Liu, Y., Maher, P., and Schubert, D. (1998) J. Cell Biol. 15, 1423-1432[CrossRef]
  59. Wang, J. F., Jerrells, T. R., and Spitzer, J. J. (1996) Free Radical Biol. Med. 20, 533-542[CrossRef][Medline] [Order article via Infotrieve]
  60. McCord, J. M., and Russell, W. J. (1988) OxyRadicals in Molecular Biology and Pathology, pp. 27-35, Alan, R. Liss, Inc., New York
  61. Zhang, Y., Marcillat, O., Giulivi, C., Ernster, L., and Davies, K. J. A. (1990) J. Biol. Chem. 265, 16330-16336[Abstract/Free Full Text]
  62. Hampton, M. B., and Orrenius, S. (1997) FEBS Lett. 414, 552-556[CrossRef][Medline] [Order article via Infotrieve]
  63. Gray, N. K., Quick, S., Goossen, B., Constable, A., Hirling, H., Kuhn, L. C., and Hentze, M. W. (1993) Eur. J. Biochem. 218, 657-667[Abstract]
  64. Tucker, P. C., Griffin, D. E., Choi, S., Bui, N., and Wesselingh, S. (1996) J. Virol. 70, 3972-3977[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.